Merckâ€™s 2010 Q1 earnings transcript reveals enhanced earnings and revenue driven by the successful integration of recently merged operations and robust performance of key brands. However, the upcoming healthcare reform and patent expirations pose challenges. The company's focus on cost management, late-stage pipeline projects, and global expansion is positive, but the stock will likely experience a short-term dip due to uncertainties around healthcare reform and a weaker Q2 outlook. [-1]